Biodel Announces Commercial Supply Agreement With BD for Liquid Glucagon Rescue Device
December 17, 2013 08:17 ET
|
Biodel Inc.
DANBURY, Conn., Dec. 17, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today announced a long-term supply agreement with BD (Becton, Dickinson and Company), a leading global medical technology...
Biodel to Report Fourth Quarter Fiscal Year 2013 Financial Results on December 18, 2013
December 12, 2013 07:00 ET
|
Biodel Inc.
DANBURY, Conn., Dec. 12, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) will issue its fourth quarter fiscal year 2013 financial results on December 18, 2013. Following the release of the...
Biodel Advances Ultra-Rapid-Acting Concentrated Insulin Formulation Into Clinical Development
November 07, 2013 16:00 ET
|
Biodel Inc.
DANBURY, Conn., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today announced the initiation of a Phase 1 clinical trial under its existing U.S. Investigational New Drug Application, as...
Biodel's BIOD-123 Achieves Primary Endpoint in Phase 2 Clinical Trial Demonstrating Glycemic Control Comparable to Humalog(R)
September 08, 2013 17:00 ET
|
Biodel Inc.
DANBURY, Conn., Sept. 8, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today announced preliminary results from Study 3-201, a Phase 2 clinical study of BIOD-123, an investigational...
Biodel Reports Third Quarter Fiscal Year 2013 Financial Results
August 12, 2013 16:30 ET
|
Biodel Inc.
DANBURY, Conn., Aug. 12, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today reported financial results for the third fiscal quarter ended June 30, 2013.
Portfolio highlights since last fiscal...
Biodel to Present at Wedbush 2013 Life Sciences Management Access Conference
August 08, 2013 06:00 ET
|
Biodel Inc.
DANBURY, Conn., Aug. 8, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) announced today that management will be presenting an overview of the company's technologies, development programs, and...
Biodel to Report Third Quarter Fiscal Year 2013 Financial Results on August 12, 2013
August 07, 2013 06:00 ET
|
Biodel Inc.
DANBURY, Conn., Aug. 7, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) will issue its third quarter fiscal year 2013 financial results on August 12, 2013. Following the release of the company's...
Biodel Announces Completion of Dosing in Phase 2 Clinical Trial of BIOD-123 in Patients With Type 1 Diabetes
July 11, 2013 06:00 ET
|
Biodel Inc.
DANBURY, Conn., July 11, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today announced that all scheduled follow-up visits have been completed for patients enrolled in the Phase 2 clinical trial...
Biodel to Present New Preclinical Glucagon Data During Corporate Overview at JMP Securities Healthcare Conference
July 03, 2013 06:00 ET
|
Biodel Inc.
DANBURY, Conn., July 3, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) announced today that management will present new preclinical pharmacokinetic and pharmacodynamic data on its glucagon...
Biodel Has Been Added to Russell Microcap Index
July 02, 2013 06:00 ET
|
Biodel Inc.
DANBURY, Conn., July 2, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD), a biotechnology company developing novel treatments for diabetes, announced today that the company has joined the Russell...